Botulinum toxin for conditions of the female pelvis

Dominique El-Khawand, Salim Wehbe, Kristene Whitmore

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Introduction and hypothesis Botulinum toxin has recently been approved by the Food and Drug Administration (FDA) for the treatment of urinary incontinence associated with neurogenic detrusor overactivity. However, it has also been used off-label for a multitude of other conditions in the female pelvis, including urological, gynecological, and colorectal. This article reviews the most recent data regarding its efficacy and safety, and administration techniques for thoseconditions. Methods A literature review of the most relevant reports published between 1985 and 2012. Results Urinary incontinence related to neurogenic detrusor overactivity is currently the only approved indication in the female pelvis. Other supported off-label uses include: idiopathic detrusor overactivity, interstitial cystitis/bladder pain syndrome, detrusor sphincter dyssynergia, high-tone pelvic floor dysfunction, anal fissure, anismus, and functional anal pain. Conclusions Botulinum toxin may effectively and safely be used in many conditions of the female pelvis. More high quality research is needed to better clarify its role in the therapeutic algorithm for those indications.

Original languageEnglish (US)
Pages (from-to)1073-1081
Number of pages9
JournalInternational Urogynecology Journal and Pelvic Floor Dysfunction
Issue number7
StatePublished - Jul 2013
Externally publishedYes


  • Anal fissure
  • Anismus
  • Botulinum toxin
  • High tone pelvic floor dysfunction
  • Interstitial cystitis
  • Neurogenic detrusor overactivity

ASJC Scopus subject areas

  • Urology
  • Obstetrics and Gynecology


Dive into the research topics of 'Botulinum toxin for conditions of the female pelvis'. Together they form a unique fingerprint.

Cite this